| Market Cap | 7.07M | P/E | - | EPS this Y | 95.00% | Ern Qtrly Grth | - |
| Income | -10.77M | Forward P/E | -3.91 | EPS next Y | 17.40% | 50D Avg Chg | 8.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -16.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -73.00% |
| Recommedations | 3.00 | Quick Ratio | 0.47 | Shares Outstanding | 39.04M | 52W Low Chg | 55.00% |
| Insider Own | 0.20% | ROA | -112.61% | Shares Float | 39.03M | Beta | 0.60 |
| Inst Own | 0.57% | ROE | -329.00% | Shares Shorted/Prior | 658.90K/2.19M | Price | 4.18 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 171,967 | Target Price | - |
| Oper. Margin | - | Earnings Date | May 9 | Volume | 9,851 | Change | -0.48% |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
| Maxim Group | Buy | Jul 14, 23 |